University of PA Study Reveals Pembrolizumab Can Lengthen Progression-Free Survival in Non-Small Cell Lung Cancer

University of PA Study Reveals Pembrolizumab Can Lengthen Progression-Free Survival in Non-Small Cell Lung Cancer

University of Pennsylvania investigators report that the administration of pembrolizumab behind locally ablative therapy (LAT) for oligometastatic non-small cell lung cancer (NSCLC) seems to lengthen progression-free survival (PFS) without degradation of quality of...

Pin It on Pinterest